The Market for Organ and Tissue Transplantation and Alternatives
The organ and tissue transplantation market in the U.S. is estimated at $11.7 billion in 2005 ad is expected to rise at an average annual growth rate (AAGR) of 5.2% to $15.1 billion by 2010.
The transplantation market is estimated at just under $5 billion in 2005 and is expanding at an AAGR of 4.8%.
The fastest growing sector is small bowel (intestine) transplantation. Kidney and liver transplantation will account for 78% of the total in 2005.
The U.S. tissue transplantation market totaled about $6.8 billion in 2005. It is projected to grow at an AAGR of 5.5%, to $8.9 billion in 2010.
Organ failure and tissue loss account for half the medical spending in the U.S. In theory, transplantation is the last therapeutic option available to people in the final stage of an organ or tissue failure. In reality, the supply of organs or tissues is so limited that for the vast majority of people, transplantation is not an option. At the same time, transplantation outcomes are under renewed scrutiny as insurers try to control healthcare costs.
The organ transplantation currently faces some of its toughest challenges and hurdles. At the same time, exciting fields of research offer hope for overcoming those challenges. Hence, tremendous opportunities exist to meet growing market demand and to cut costs. But, at the same time, competitors have great opportunities to provide equivalent outcomes at reduced cost. This report is a valuable tool for anyone assessing the organ and tissue transplantation market and attempting to devise a strategy to address it successfully.
This BCC study provides an in-depth analysis and forecast of the organ and tissue transplantation markets. The focus is on products and procedures used or under development including techniques, therapies, drugs and diagnostics.
SCOPE OF STUDY
The report contains:
- Full coverage of product segments including solid organs, experimental xenografts and artificial organs; tissue transplants and cell transplants
- Forecasts by product type and application through 2010, including supporting analyses for projections
- An overview of international markets
- Discussion of the industry's structure and the regulatory environment
- Profiles of leading companies involved including placement within the market and strategic analyses of available and emerging products.
Information for this report was derived from a variety of sources, including that provided by product managers, marketing strategists, research executives and others at leading companies in the tissue transplantation market and at companies poised to enter the market. Others consulted include transplant surgeons, directors of transplant programs or tissue typing laboratories, and other medical professionals who participate in processes involved with transplantation, or who compete against it. Other data came from company annual reports and 10Ks, journal articles, prospectus assessments, government resources and from healthcare institutions.
Information for this report was obtained from primary interviews with companies, industry analysts, healthcare personnel, Center for Medicare and Medicaid Services (CMS) and other government agencies, literature searches, annual reports, 10Ks and product literature.
Lynn Gray has been a research analyst in the biotechnology and life sciences since 1989. Her collaboration with Communications Co. (BCC) began in 1996, and during that time, she has authored over 20 BCC biomedical reports.
Tissue and organ transplantation in the U.S. was a $17.3 billion market in 2002.
This is expected to grow 18% to $20.5 billion by 2007 at an average annual rate (AAGR) of 3.5%.
The fastest growing sector is small bowel transplantation.
Kidney transplantation accounted for 59% of U.S. organ transplants in 2002.